查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球单采市场 - 2023-2030
市场调查报告书
商品编码
1347967

全球单采市场 - 2023-2030

Global Apheresis Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

全球单采市场在 2022 年达到 18 亿美元，预计到 2030 年将达到 50 亿美元，2023-2030 年预测期间复合年增长率为 8.4%。

单采术是一种医疗技术医疗程序，涉及分离、提取和收集人体血液的特定成分。设备推出数量的增加和血液疾病的增加预计将推动市场增长。

北美地区预计将占据重要的市场份额。血浆置换领域占有重要的市场份额。设备技术进步的增加及其优势使该领域处于重要地位。

根据 DataM Intelligence，Apheresis 市场研究分析提供了包含定量和定性数据的市场深入展望。它根据市场细分对全球市场进行了展望和预测。

动力学

设备发布数量的增加预计将推动市场增长

设备发布数量的增加预计将推动市场增长。例如，2022 年 9 月 20 日，医疗技术公司 Terumo Blood and Cell Technologies (Terumo BCT) 推出了 Quantum Flex Cell Expansion System，这是一个生物反应器平台，支持细胞和基因治疗的工艺开发到商业製造。资本利得税）部门。

此外，例如，Terumo Blood and Cell Technologies 于 2023 年 8 月 1 日推出了 Reveos 设备，可在单个离心循环中将血液处理成血小板，该设备已获得美国食品和药物管理局 (FDA) 的批准。因此，发布数量的增加预计将推动市场增长。

血液疾病的增加预计将推动市场增长

血液疾病的增加预计将推动市场增长。例如，根据 CDC 的数据，镰状细胞病影响着大约 100,000 名美国人。每 365 名黑人或非裔美国人新生儿中就有 1 名患有 SCD。每 16,300 名出生的西班牙裔美国人中大约就有 1 人患有此病。大约三分之一的黑人或非裔美国婴儿出生时就患有镰状细胞性状 (SCT)。

红细胞交换用于治疗或有时预防镰状细胞病的严重并发症，例如中风和急性胸部综合征。在红细胞交换中，通过单采术去除患病或异常的红细胞，然后用供体红细胞替换。此外，美国癌症协会预计 2023 年美国白血病新发病例（各类）约为 59,610 例，死于白血病（各类）的人数为 23,710 例，急性髓系白血病 (AML) 新增病例为 20,380 例。白细胞去除术涉及从循环血液中去除患者的白细胞。因此，血液系统疾病的增加

与血浆分离术相关的高成本预计将阻碍市场增长

这些程序的高成本也是限制市场增长的一大因素。例如，每次血浆置换术的平均成本在 1,500 美元到 2,500 美元之间。单采术过程存在多种风险，其中最重要的风险是血液污染，这在手术过程中很常见。

血浆分离术的其他并发症也会影响市场增长。最常见的单采特异性反应是柠檬酸盐抗凝引起的低钙血症，虽然通常较轻微，但有可能严重伤害供体。重复的单采血液成分捐献可能会对捐献者产生长期不良影响，例如骨脱矿和白内障形成。因此，上述因素预计将阻碍市场增长。

目录

第 1 章：方法和范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义和概述

第 3 章：执行摘要

  • 按设备分類的片段
  • 技术片段
  • 程序片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 设备启动数量增加
      • 血液系统疾病增加
    • 限制
      • 与单采术相关的高成本
    • 机会
    • 影响分析

第 5 章：行业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 俄乌战争影响分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商战略倡议
  • 结论

第 7 章：按设备

  • 单采设备
  • 血浆分离器
  • 血浆成分分离器
  • 免疫吸附柱
  • 血浆灌注柱
  • 血液灌流柱
  • 单采一次性用品

第 8 章：按技术

  • 离心
  • 间歇流
  • 连续流
  • 膜分离

第 9 章：按程序

  • 血浆分离术
  • 血小板去除术
  • 红细胞去除术
  • 白细胞去除术
  • 其他的

第 10 章：按地区

  • 北美
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Fresenius SE & Co. KGaA
    • 公司简介
    • 设备产品组合和描述
    • 财务概览
    • 主要进展
  • Cerus Corporation
  • Asahi Kasei Medical Co., Ltd.
  • Haemonetics Corporation
  • B. Braun Melsungen
  • Kaneka Corporation
  • Terumo BCT, Inc.
  • Kawasumi Laboratories Inc.
  • Nikkiso Europe GmbH
  • Baxter.

第 13 章：附录

简介目录
Product Code: MD2202

Overview

Global Apheresis Market reached US$ 1.8 billion in 2022 and is expected to reach US$ 5.0 billion by 2030, growing with a CAGR of 8.4% during the forecast period 2023-2030.

Apheresis is a medical technology medical procedure that involves the separation, extraction, and collection of specific components of a person's blood. The increased number of launches of the devices and an increase in hematological disorders are expected to drive market growth.

North America region is expected to hold a significant position in the market share. The plasmapheresis segment holds a significant market share. The increase in technological advancements in the Devices and their advantages are holding the segment in a significant position.

As per DataM Intelligence, Apheresis Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation.

Dynamics

Increased Number of Device Launches is Expected to Drive the Market Growth

An increased number of Device launches are expected to drive the market growth. For instance, on September 20, 2022, Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, launched its Quantum Flex Cell Expansion System, a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector.

Additionally, for instance, on August 1, 2023, Terumo Blood and Cell Technologies launched a Reveos device that processes blood into platelets in a single centrifugation cycle, which has been cleared by the US Food and Drug Administration (FDA). Thus, an increase in the number of launches is expected to drive the market growth.

Increase in Hematological Disorders is Expected to Drive Market Growth

An increase in hematological disorders is expected to drive market growth. For instance, according to the CDC, Sickle Cell Disease affects approximately 100,000 Americans. SCD occurs among about 1 out of every 365 Black or African-American births. It occurs among about 1 out of every 16,300 Hispanic-American births. About 1 in 13 Black or African-American babies is born with sickle cell trait (SCT).

Red blood cell exchange is used to treat or sometimes prevent serious complications of sickle cell disease, such as stroke and acute chest syndrome. In red blood cell exchange, diseased or abnormal red blood cells are removed by apheresis and then replaced by donor red blood cells. Additionally, The American Cancer Society's estimates for leukemia in the United States for 2023 are about 59,610 new cases of leukemia (all kinds) and 23,710 deaths from leukemia (all kinds), 20,380 new cases of acute myeloid leukemia (AML). Leukapheresis involves the removal of a patient's white blood cells from the circulating blood. Thus, the increase in hematological disorders

High costs Associated with Apheresis are Expected to Hamper the Market Growth

The high cost of these procedures is also a big factor restraining the growth of the market. For instance, the average cost of plasmapheresis ranges between $1,500 and $2,500 per procedure. Various risks are associated with the Apheresis procedure, and the crucial one is blood contamination, which is very common during the procedure.

Other complications with the apheresis can also affect the market growth. The most common apheresis-specific reaction is hypocalcemia due to citrate anticoagulation, which, while usually mild, has the potential to injure the donor severely. Repeated apheresis donation may produce adverse long-term effects in donors, such as bone demineralization and cataract formation. Thus, the above factors are expected to hamper the market growth.

Segment Analysis

The global apheresis market is segmented based on device, technology, procedure, and region.

Centrifugation Segment Holds a Significant Position in the Market Share

Centrifugal apheresis can be used to remove cellular components and is very efficient, achieving plasma extraction of nearly 80%. One of the benefits of centrifugal apheresis is that it requires lower blood flow rates and, therefore, can be performed using either peripheral or central venous access.

Most apheresis devices use centrifugation and require blood flow rates of 50-120 mL/min. Centrifugation takes advantage of the different specific gravities inherent to various blood products, such as red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma. Thus, the advantages and efficiency of the centrfugation in seperating the whole blood components is holding a dominant position in the market share.

Geographical Penetration

North America region holds the largest market share in the global Apheresis market

North America holds a significant share of the global apheresis market. The increase in the number of blood transfusions and the increase in the demand for various blood components are holding the region's market growth. For instance, according to the American National Red Cross, approximately 29,000 units of red blood cells are needed every day in the U.S., nearly 5,000 units of platelets and 6,500 units of plasma are needed daily in the U.S., and about 16 million blood components are transfused each year in the U.S.

Additionally, according to the American Cancer Society, more than 1.9 million people are expected to be diagnosed with cancer in 2023. Many of them will need blood, sometimes daily, during their chemotherapy treatment. Thus, an increase in the demand for blood transfusions in the region is expected to hold the region in the dominant position.

Competitive Landscape

The global apheresis market is fragmented, with the presence of many local and international players. Fresenius SE & Co. KGaA, Cerus Corporation, Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, B. Braun, Melsungen, Kaneka Corporation, Terumo BCT, Inc., Kawasumi Laboratories Inc., and Nikkiso Europe GmbH, Baxter. are the leading Companies with a significant market share.

COVID-19 Impact Analysis

The COVID-19 epidemic is expected to benefit the development of the global apheresis business. Global healthcare systems were under pressure from the COVID-19 epidemic. Due to COVID-19, patients with severe infections had complications with their coagulation parameters, including platelet count, fibrinogen, D-dimer, prothrombin time (PT), and activated partial thromboplastin time (aPTT). As a result, plasma therapy was used extensively as a treatment. Patients who contracted the COVID-19 virus are treated with convalescent plasma (CP).

By Device

  • Apheresis Devices
  • Plasma Separators
  • Plasma Component Separators
  • Immunoadsorption Columns
  • Plasma Perfusion Columns
  • Hemoperfusion Columns
  • Apheresis Disposables

By Technology

  • Centrifugation
  • Intermittent Flow
  • Continuous Flow
  • Membrane Separation

By Procedure

  • Plasmapheresis
  • Plateletpheresis
  • Erythrocytapheresis
  • Leukapheresis
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global apheresis market segmentation based on device, technology, procedure, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of apheresis market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Device mapping available as excel consisting of key Devices of all the major players.

The global apheresis market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Procedure
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased number of device launches
      • 4.1.1.2. Increase in hematological disorders
    • 4.1.2. Restraints
      • 4.1.2.1. High cost associated with apheresis
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 7.1.2. Market Attractiveness Index, By Device
  • 7.2. Apheresis Devices *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Plasma Separators
  • 7.4. Plasma Component Separators
  • 7.5. Immunoadsorption Columns
  • 7.6. Plasma Perfusion Columns
  • 7.7. Hemoperfusion Columns
  • 7.8. Apheresis Disposables

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Centrifugation *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Intermittent Flow
  • 8.4. Continuous Flow
  • 8.5. Membrane Separation

9. By Procedure

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.1.2. Market Attractiveness Index, By Procedure
  • 9.2. Plasmapheresis*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Plateletpheresis
  • 9.4. Erythrocytapheresis
  • 9.5. Leukapheresis
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Fresenius SE & Co. KGaA *
    • 12.1.1. Company Overview
    • 12.1.2. Device Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Cerus Corporation
  • 12.3. Asahi Kasei Medical Co., Ltd.
  • 12.4. Haemonetics Corporation
  • 12.5. B. Braun Melsungen
  • 12.6. Kaneka Corporation
  • 12.7. Terumo BCT, Inc.
  • 12.8. Kawasumi Laboratories Inc.
  • 12.9. Nikkiso Europe GmbH
  • 12.10. Baxter.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us